{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:10:29Z","timestamp":1786133429500,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1681\/asn.2011060603","type":"journal-article","created":{"date-parts":[[2011,7,15]],"date-time":"2011-07-15T00:25:15Z","timestamp":1310689515000},"page":"1393-1396","source":"Crossref","is-referenced-by-count":9,"title":["Fibrosis, Regeneration, and Aging"],"prefix":"10.1681","volume":"22","author":[{"given":"Vicente E.","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Leof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20230423","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1681\/ASN.2010111158","article-title":"Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease","volume":"22","author":"Iyoda","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R4-2-20230423","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1472-8206.2010.00824.x","article-title":"Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression","volume":"25","author":"Shaker","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"R5-2-20230423","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"R6-2-20230423","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-2-20230423","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-2-20230423","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"R9-2-20230423","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"R10-2-20230423","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1098\/rstb.2004.1475","article-title":"Scar-free healing: From embryonic mechanisms to adult therapeutic intervention","volume":"359","author":"Ferguson","year":"2004","journal-title":"Phi Trans R Soc Lond B Biol Sci"},{"key":"R11-2-20230423","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/dvdy.10239","article-title":"Regeneration or scarring: An immunologic perspective","volume":"226","author":"Harty","year":"2003","journal-title":"Dev Dyn"},{"key":"R12-2-20230423","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1681\/ASN.2007050532","article-title":"A new look at platelet-derived growth factor in renal disease","volume":"19","author":"Floege","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R14-2-20230423","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1681\/ASN.2007030290","article-title":"PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis","volume":"19","author":"Eitner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R15-2-20230423","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004410050009","article-title":"PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction","volume":"299","author":"Ludewig","year":"2000","journal-title":"Cell Tissue Res"},{"key":"R16-2-20230423","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1152\/ajprenal.00320.2009","article-title":"Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis","volume":"298","author":"Wang","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R17-2-20230423","doi-asserted-by":"crossref","first-page":"17841","DOI":"10.1074\/jbc.M111.233676","article-title":"Non-Smad transforming growth factor-beta signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase","volume":"286","author":"Hong","year":"2011","journal-title":"J Biol Chem"},{"key":"R18-2-20230423","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-2-20230423","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","article-title":"Colony-stimulating factor-1 in immunity and inflammation","volume":"18","author":"Chitu","year":"2006","journal-title":"Cur Opin Immunol"},{"key":"R20-2-20230423","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1172\/JCI39087","article-title":"CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice","volume":"119","author":"Menke","year":"2009","journal-title":"J Clin Invest"},{"key":"R21-2-20230423","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajpath.2011.03.023","article-title":"Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy","volume":"179","author":"Stokman","year":"2011","journal-title":"Am J Pathol"},{"key":"R22-2-20230423","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200603-333OC","article-title":"Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis","volume":"174","author":"Avivi-Green","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-2-20230423","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.matbio.2010.03.002","article-title":"Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease","volume":"29","author":"Gross","year":"2010","journal-title":"Matrix Biol"},{"key":"R24-2-20230423","doi-asserted-by":"crossref","first-page":"e14386","DOI":"10.1371\/journal.pone.0014386","article-title":"Stem cell factor expression after renal ischemia promotes tubular epithelial survival","volume":"5","author":"Stokman","year":"2010","journal-title":"PloS One"},{"key":"R25-2-20230423","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1523-1755.2003.00183.x","article-title":"Mast cell infiltration and chemokine expression in progressive renal disease","volume":"64","author":"Jones","year":"2003","journal-title":"Kidney Int"},{"key":"R26-2-20230423","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2010.120","article-title":"Renal fibrosis: Novel insights into mechanisms and therapeutic targets","volume":"6","author":"Boor","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R27-2-20230423","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1681\/ASN.2010080793","article-title":"Mechanisms of tubulointerstitial fibrosis","volume":"21","author":"Zeisberg","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R28-2-20230423","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1681\/01.asn.0000926916.36548.91","article-title":"Resolved: EMT produces fibroblasts in the kidney","volume":"21","author":"Zeisberg","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R29-2-20230423","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ki.2011.77","article-title":"Scar wars: Mapping the fate of epithelial-mesenchymal-myofibroblast transition","volume":"80","author":"Quaggin","year":"2011","journal-title":"Kidney Int"},{"key":"R30-2-20230423","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1440-1681.2011.05531.x","article-title":"Pivotal role of pericytes in kidney fibrosis","volume":"38","author":"Kida","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R31-2-20230423","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.109.191643","article-title":"Perivascular ancestors of adult multipotent stem cells","volume":"30","author":"Corselli","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R32-2-20230423","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(09)60322-6","article-title":"Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I\/II studies","volume":"373","author":"Ferguson","year":"2009","journal-title":"Lancet"},{"key":"R34-2-20230423","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-010-0142-x","article-title":"Tyrosine kinase inhibitors in the treatment of systemic sclerosis: From animal models to clinical trials","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"R35-2-20230423","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2340\/00015555-1085","article-title":"Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis","volume":"91","author":"Elmholdt","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R36-2-20230423","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"R37-2-20230423","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"R38-2-20230423","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R39-2-20230423","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R40-2-20230423","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"R42-2-20230423","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","article-title":"Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss","volume":"51","author":"Francois","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R43-2-20230423","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","article-title":"Renal failure associated with tyrosine kinase inhibitors: Case report and review of the literature","volume":"34","author":"Gafter-Gvili","year":"2010","journal-title":"Leuk Res"},{"key":"R44-2-20230423","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.leukres.2008.07.029","article-title":"Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia","volume":"33","author":"Holstein","year":"2009","journal-title":"Leuk Res"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201108000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:33:51Z","timestamp":1786131231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201108000-00002"}},"subtitle":["Playing Chess with Evolution"],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2011060603","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}